Vaccine Trade
Moderna's AI picked 34 targets out of a patient's tumor. It worked.
- First ever Phase 3 win for an AI-designed personalized cancer vaccine. MRNA more than doubled.
- Moderna calls it a technological breakthrough, not just a medical one. One AI picks the targets, a second runs the factory.
- The trade is the assembly line, not the drug. Read the tumor, pick the targets, write the DNA, decide who needs it.
- TEM, TWST, NTRA. Only TEM has a documented link. The other two are logic.
- Everything here is already up 15-20% or more. Chasing this is risky. Not financial advice.
Not financial advice. Research and opinion only. Do your own research and manage your own risk.
Every AI healthcare name on my list
These are the ten I track in this basket. Nine of the ten were green on the day. This is what each one actually does.
| Ticker | Company | What it does | Move |
|---|---|---|---|
| MRNA | Moderna | The mRNA cancer vaccine itself | +127.8% |
| NTRA | Natera | Signatera personalized MRD blood test | +21.4% |
| TWST | Twist Bioscience | Synthetic DNA on silicon chips | +19.2% |
| TEM | Tempus AI | AI oncology, tumor sequencing plus data | +16.9% |
| SOPH | SOPHiA Genetics | Hospital SaaS for genomic analysis | +15.3% |
| WGS | GeneDx | Rare disease exome and genome sequencing | +10.8% |
| TXG | 10x Genomics | Single-cell and spatial research tools | +8.9% |
| SDGR | Schrödinger | Physics-based small molecule design | +7.3% |
| GH | Guardant Health | Liquid biopsy, MRD, cancer screening | +6.9% |
| LLY | Eli Lilly | Big pharma, the scale buyer of all this | +3.4% |
Look at that Move column again. Most of these names are up 15 to 20 percent in a single session and Moderna more than doubled. Buying anything here means paying a price that already has the news in it. Chasing a move like this is very risky — the easy money was made by people who owned it yesterday, and gaps this size very often give a chunk back.
I am not telling you to buy any of these. This is not financial advice. Do your own research, wait for your own levels, and never chase someone else's green candle.
Why they all moved together
One event lifted the entire basket, and it was not an AI product launch. It was a cancer trial — but the therapy behind it is built by AI, per patient. That distinction is the whole piece.
The first Phase 3 win for a personalized cancer vaccine
INTerpath-001 met both recurrence-free and distant metastasis-free survival in resected stage IIB-IV melanoma, randomized 2:1 against Keytruda alone. Earlier five-year data showed a 49% lower risk of recurrence or death. This is the first positive Phase 3 for any individualized neoantigen therapy, which is why the whole genomics complex moved.
| Program | Cancer | Status |
|---|---|---|
| INTerpath-001 | Melanoma | Phase 3 hit, Aug 19 2026 |
| INTerpath-002 | Lung (NSCLC) | Phase 3 enrolling |
| Expansion | More tumor types | Planned |
Moderna is building a dedicated commercial manufacturing plant in Marlborough, Massachusetts. Nobody builds a bespoke factory for a therapy they expect to stay in trials. Lung is the far bigger population and the next readout that matters.
An AI story, in Moderna's own words
Moderna's own post is titled Advancing the Fight Against Cancer through mRNA & AI, with a section headed A Testament to the Power of AI.
"A series of fully integrated AI algorithms takes next-generation sequencing data from tumor and blood samples, reviews their genetic mutations, and predicts up to 34 of those neoantigens most likely to elicit an immune response."
It also learns — the algorithm improves by pairing clinical and immunogenicity data, so every patient treated sharpens the next selection.
There is a second AI nobody mentions. Moderna built Maestro, which schedules every patient batch against real-time plant capacity and re-plans automatically when anything slips, so a bespoke drug lands before that person's dose date. Designing thousands of different drugs at once is one problem. Manufacturing them on deadline is another.
Your cancer has a fingerprint nobody else has. One AI reads it and picks the 34 parts your immune system can be taught to hunt. A second AI runs the factory so your batch is ready on the day you need it. This does not scale like a drug. It scales like a factory.
Three names, three different jobs
| TEM | TWST | NTRA | |
|---|---|---|---|
| Revenue | $382.5M | $118.4M | $752.8M |
| Growth | +22% | +23% | +37.7% |
| Gross margin | ~64% | 52.8% | 64.5% |
| Bottom line | Profit $5.6M | Loss $35.1M | EPS -$0.47 |
| Vaccine link | Documented | Inferred | Inferred |
TEM — the one with the receipt
Personalis also brings NeXT Personal, an ultra-sensitive MRD test — so Tempus owns both the profiling that designs the vaccine and a test that measures whether it worked. It is also the only one of the three posting GAAP net income, at $5.6M.
TWST — builds what the AI designs
| Segment | Revenue | Growth |
|---|---|---|
| DNA Synthesis & Protein | $56.6M | +39% |
| NGS Applications | $61.8M | +12% |
Total $118.4M, up 23%. FY guidance raised to $456-457M.
If AI collapses drug design from months to hours, the bottleneck moves to whoever can physically synthesise and test the flood. Twist is one of two labs Anthropic used to do it.
NTRA — the gatekeeper
Signatera is a personalized ctDNA test built from each patient's own tumor mutations — same input as the vaccine, different job.
Signatera Genome showed 94% sensitivity and 100% specificity across five tumor types including melanoma. Commercially it is the most proven of the three: $752.8M revenue up 37.7%, oncology volume up 57.2%, full-year guidance raised to $2.85-2.91B, operating margin improved to -10.1% from -20.2%.
Why the other six did not make it
| Name | Why not |
|---|---|
| GH | Grew faster than Natera at 44%, but that leans on colorectal screening and there is no comparable melanoma MRD data. |
| TXG | Genuinely relevant — single-cell is how you measure T-cell response — but strip out a litigation settlement and real growth was 3%, it swung to a loss, and it is up 161% in 90 days. |
| SOPH | Right layer, wrong size. Roughly $0.6B market cap and thin liquidity. |
| WGS | Rare disease and pediatrics. Different clinical field entirely. |
| SDGR | Physics-based small molecule design. Wrong modality for an mRNA vaccine. |
| LLY | Too big for this to move the needle. It is the buyer of the theme, not a play on it. |
What could break this
| Risk | Why it matters |
|---|---|
| Full data not out | Endpoints were met. Magnitude, safety and subgroups come later. Significant is not the same as commercially meaningful. |
| Two links inferred | Only Tempus is documented. If the supply chain is locked with private partners or brought in-house, TWST and NTRA are a theme, not a contract. |
| Already repriced — the big one | MRNA doubled, NTRA +21%, TWST +19%, TEM +17% in one session. Years of adoption are already in the tape. Buying after a move this size is the riskiest part of this entire trade, and it is the reason I am not telling anyone to buy here. |
| Approval then payers | Regulators first, then someone has to fund a bespoke per-patient therapy. Neither is guaranteed. |
Johnny's read
Research and opinion only — this is not financial advice and nothing here is a recommendation to buy anything. Every name in this piece has already run hard, several by 15 to 20 percent or more in one session, and buying after a gap like that carries real risk of an immediate drawdown. Clinical results can also fail to become approvals, revenue or share price. Do your own research, use your own levels, and size your own risk.
NFA · DYOR. Not financial advice, not a solicitation, not a recommendation. Clinical and regulatory outcomes are uncertain and markets involve risk of loss including total loss of capital.